Antecedent 99mTc-MDP and 99mTc-sestamibi administration corrupts bone mineral density measured by DXA.
Previous reports of the effect of antecedent administration of radionuclide on bone mineral density (BMD) measurements have yielded inconsistent results. Ten subjects scheduled for (99m)Tc-methylene diphosphonate ((99m)Tc-MDP) bone scanning and 10 scheduled for (99m)Tc-sestamibi cardiac scanning had BMD measured by dual X-ray absorptiometry (DXA) (GE/Lunar) before and within 5 hours of diagnostic radionuclide injection. Paired t test and Wilcoxon-signed rank tests were used to compare the measured differences in BMD at multiple skeletal sites. Differences were subjected to multivariate analysis of demographic factors. Mean change in measured BMD following (99m)Tc-sestamibi administration (DeltaBMD-(99m)Tc-sestamibi) was -0.216+/-0.113 g/cm(2) at the total body and -0.348+/-0.300 g/cm(2) at the lumbar spine (p<0.005). Mean change in measured BMD following (99m)Tc-MDP administration (DeltaBMD-(99m)Tc-MDP) was -0.058+/-0.037 g/cm(2) at the total body and -0.053+/-0.049 g/cm(2) at the lumbar spine (p<0.05). Mean DeltaBMD-(99m)Tc-sestamibi exceeded least significant change (LSC) in all skeletal sites except the femoral trochanter. Mean DeltaBMD-(99m)Tc-MDP exceeded LSC only at the lumbar spine. The effect was correlated with (99m)Tc dose but not with gender, age, body mass index, baseline BMD, or time interval from injection to scan acquisition. In conclusion, BMD measured by the GE/Lunar Prodigy densitometer is corrupted by antecedent (99m)Tc-sestamibi and to a lesser extent by (99m)Tc-MDP. This effect is greater at the total body and lumbar spine than at the hip. Caution is warranted in scheduling and interpreting DXA studies when (99m)Tc has been recently administered.
McKiernan
Fergus Eoin
FE
Center for Bone Diseases, Marshfield Clinic, Marshfield, WI 54449, USA. mckiernan.fergus@marshfieldclinic.org
Hocking
Jane
J
Cournoyer
Susan
S
D015502:Absorptiometry, Photon; D000368:Aged; D015519:Bone Density / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D019275:Radiopharmaceuticals / Q000494:pharmacology*; D013669:Technetium Tc 99m Medronate / Q000494:pharmacology*; D017256:Technetium Tc 99m Sestamibi / Q000494:pharmacology*
D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi; D013669:Technetium Tc 99m Medronate